ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2751

Very Low Prevalence of Ultrasound Determined Tendon Abnormalities in Healthy Subjects Throughout the Age Range: An Outcome Measures in Rheumatology (OMERACT) Ultrasound Minimal Disease Study

Jeanette Trickey1, Ilfita Sahbudin 2, Alessandra Bortoluzzi 3, ANNAMARIA IAGNOCCO 4, Carlos Pineda 5, Cesar Sifuentes-Cantú 6, Coziana Ciurtin 7, Cristina Reátegui-Sokolova 8, Daniela Fodor 9, ESPERANZA NAREDO 10, Ellen-Margrethe Hauge 11, Florentin Vreju 12, Garifallia Sakellariou 13, George A. W. Bruyn 14, Georgios Filippou 15, Giuliana La Paglia 6, Gustavo Leon 16, Hélène Gouze 17, Helen Keen 18, Hilde Hammer 19, Ilaria Tinazzi 20, Irene Azzolin 4, Jacek Fliciński 21, Kei Ikeda 22, Lene Terslev 23, Mads Ammitzball Danielsen 24, Mads Nyhuus Bendix Rasch 11, Marcin Milchert 21, Maria Stoenoiu 25, Marion Kortekaas 26, Marwin Gutierrez 5, Mihaela Maruseac 27, Mohamed Mortada 28, Philippe Carron 29, Rositsa Karalilova 30, Ruth Wittoek 31, Sarah Ohrndorf 32, Takeshi Suzuki 33, Teodora Șerban 34, Maria-Antonietta D’Agostino 35 and Andrew Filer 36, 1Institute of Inflammation and Ageing, University of Birmingham, Hereford, United Kingdom, 2Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, 3University of Ferrara, Ferrara, Italy, 4Academic Rheumatology Centre, Università degli Studi di Torino, TURIN, Italy, 5Division of Musculoskeletal and Rheumatic Diseases, Instituto Nacional de Rehabilitación “Luis Guillermo Ibarra Ibarra”, Mexico, Mexico, Mexico, 6Department of Rheumatology, Bone and Joint Research Unit. Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, 7Centre for Adolescent Rheumatology, University College London London, UK, Londond, United Kingdom, 8Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, 92nd Internal Medicine Department, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Cluj-Napoca, Romania, 10Rheumatology Department, Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz, Universidad Autónoma, MADRID, Spain, 11Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 12Department of Rheumatology, University of Medicine and Pharmacy Craiova, Craiova, Romania, 13Division of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, 14Department of Rheumatology, MC Groep Hospitals., Lelystad, Netherlands, 15University of Ferrara, Cona, Italy, 16Instituto Nacional de Rehabilitacion, Mexico City, Lima, Peru, 17Rheumatology Department, APHP, Ambroise Paré Hospital, Bolougne Billancourt, France, 18School of Medicine and Pharmacology Fiona Stanley Hospital Unit, University of Western Australia, Perth, Australia, 19Diakonhjemmet Hospital, Oslo, Norway, 20Sacro Cuore Don Calabria Hospital, Unit of Rheumatology, Verona, Italy, 21Department of Rheumatology, Internal Diseases and Geriatrics; Pomeranian Medical University, Szczecin, Poland, 22Chiba University Hospital, Chiba, Japan, 23Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Copenhagen, Denmark, 24Copenhagen University Hospital, Copenhagen, Denmark, 25Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique, Bruxelles, Belgium, 26Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 27Department of Rheumatology, Cliniques Universitaires Saint-Luc, Institut de recherche expérimentale et clinique (IREC), Université catholique de Louvain, Brussels, Belgium, 28Rheumatology and Rehabilitation Department, Faculty of Medicine, Zagazig University, Egypt, Zagazig, Egypt, 29Ghent University Hospital, Ghent, Belgium, 30Clinic of Rheumatology, Medical University of Plovdiv, University Hospital “Kaspela", Plovdiv, Bulgaria, 31Ghent University Hospital, Gent University, Gent, Belgium, 32Charité Universitätsmedizin Berlin, Berlin, Germany, 33Division of Allergy and Rheumatology, Japanese Red Cross Medical Center, Tokyo, Japan, 34SC Reumatologia, Ospedale La Colletta, Genoa, Italy, 35Department of Rheumatology, APHP, Hôpital Ambroise Paré, Paris, France, 36Institute of Inflammation and Ageing College of Medical and Dental Sciences University of Birmingham, Birmingham, United Kingdom

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: healthy, tendon, tenosynovitis and age, Ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: 5T089: Imaging of Rheumatic Diseases II (2750–2755)

Session Type: ACR Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Tenosynovitis (TS) is a common, often clinically undetectable finding in Rheumatoid Arthritis (RA). Recent data showed TS on ultrasound (US) has a role in predicting outcome in early disease and flare in clinical remission. However data is limited on US measured TS in healthy subjects (HS), none specifically encompassing the older age range when RA commonly presents. This OMERACT study aimed to determine prevalence of US measured tendon abnormalities in HS throughout the age range.

Methods: Adult healthy subjects without: joint pain (VAS < 10/100), hand osteoarthritis (ACR criteria), or inflammatory arthritis were recruited in 23 international centres from Aug 2017-Dec 2018. MCP, PIP and wrist joints were clinically examined. Bilateral digit flexor (DF) 1-5 and extensor carpi ulnaris (ECU) tendons were scanned for tenosynovial hypertrophy (TSH) and power Doppler (PD) signal and graded (OMERACT US scoring system).  A comparison cohort of DMARD-naive patients with RA (ACR-EULAR 2010 and/or 1987 criteria) at presentation was taken from the Birmingham Early Arthritis (BEACON) inception cohort, who underwent identical tendon US assessment. They were grouped into ≤12 and > 12 weeks from symptom onset. Abnormal ultrasound findings were dichotomised in to grade 0 (absent) or grade 1-3 (present) for statistical analysis (Fisher’s exact test).

Results: Data from 899 HS and 144 RA patients were included.  Prevalence of TSH and particularly PD abnormalities in HS was very low in all age groups, and was all grade 1 except in one individual ECU tendon.  ECU TSH grade≥1 was more common than DF grade≥1 in the older HS groups, and less common in the 18-39 age group (p=0.011). TSH and PD of grade ≥1 were common in RA patients (p ≤0.001), with DF PD abnormalities more common in early disease (p=0.02).

Conclusion: Very low prevalence of TSH or PD abnormalities in tendons of healthy subjects even in old age suggests ultrasound determined tenosynovitis will be a robust tool in clinical management of RA.


ACR tendon abstract upload 1

Demographics and summary tendon data for healthy subjects by age groups, and RA patients by early and late presentation


ACR tendon abstract upload 2

Percentage of abnormal digit flexor and extensor carpi ulnaris tendons by age group of healthy subjects, and early or late presenters in RA patients


Disclosure: J. Trickey, None; I. Sahbudin, None; A. Bortoluzzi, None; A. IAGNOCCO, None; C. Pineda, None; C. Sifuentes-Cantú, None; C. Ciurtin, None; C. Reátegui-Sokolova, None; D. Fodor, None; E. NAREDO, None; E. Hauge, None; F. Vreju, Novartis, 5, Sandoz, 5, Ewopharma, 5, Abbvie, 8, Eli Lilly, 8; G. Sakellariou, None; G. Bruyn, None; G. Filippou, None; G. La Paglia, None; G. Leon, None; H. Gouze, None; H. Keen, None; H. Hammer, None; I. Tinazzi, None; I. Azzolin, None; J. Fliciński, None; K. Ikeda, Abbvie Japan, 8, AbbVie Japan, 8, Bristol-Myers Squibb Japan, 8, Mitsubishi Tanabe Pharma, 2, Novartis Japan, 8; L. Terslev, None; M. Danielsen, None; M. Rasch, None; M. Milchert, None; M. Stoenoiu, None; M. Kortekaas, None; M. Gutierrez, None; M. Maruseac, None; M. Mortada, None; P. Carron, None; R. Karalilova, None; R. Wittoek, None; S. Ohrndorf, Pfizer, 2; T. Suzuki, None; T. Șerban, None; M. D’Agostino, None; A. Filer, None.

To cite this abstract in AMA style:

Trickey J, Sahbudin I, Bortoluzzi A, IAGNOCCO A, Pineda C, Sifuentes-Cantú C, Ciurtin C, Reátegui-Sokolova C, Fodor D, NAREDO E, Hauge E, Vreju F, Sakellariou G, Bruyn G, Filippou G, La Paglia G, Leon G, Gouze H, Keen H, Hammer H, Tinazzi I, Azzolin I, Fliciński J, Ikeda K, Terslev L, Danielsen M, Rasch M, Milchert M, Stoenoiu M, Kortekaas M, Gutierrez M, Maruseac M, Mortada M, Carron P, Karalilova R, Wittoek R, Ohrndorf S, Suzuki T, Șerban T, D’Agostino M, Filer A. Very Low Prevalence of Ultrasound Determined Tendon Abnormalities in Healthy Subjects Throughout the Age Range: An Outcome Measures in Rheumatology (OMERACT) Ultrasound Minimal Disease Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/very-low-prevalence-of-ultrasound-determined-tendon-abnormalities-in-healthy-subjects-throughout-the-age-range-an-outcome-measures-in-rheumatology-omeract-ultrasound-minimal-disease-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/very-low-prevalence-of-ultrasound-determined-tendon-abnormalities-in-healthy-subjects-throughout-the-age-range-an-outcome-measures-in-rheumatology-omeract-ultrasound-minimal-disease-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology